Palvella Therapeutics (PVLA) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 84.7% versus a loss of 22.1%. Over five years, PVLA leads with a -63.8% price change compared with -78.4% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.92 billion vs $1.89 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PVLA | SRPT |
|---|---|---|
| Share price | $131.34 | $18.21 |
| Market cap | $1.89B | $1.92B |
| 1-day change | +0.57% | +4.06% |
| YTD return | +24.76% | -15.38% |
| 1-year return | +84.66% | -22.11% |
| 5-year return | -63.81% | -78.37% |
| Forward P/E | — | 7.55 |
| EPS (TTM) | $-4.85 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $161.38 | $24.68 |
| 52-week low | $65.93 | $14.68 |
| Distance from 52-week high | -18.61% | -26.22% |
| Analyst consensus | none | hold |
| Avg. price target upside | +75.52% | +19.33% |
| Average volume | 212.38K | 2.98M |
| Shares outstanding | 14.41M | 105.63M |
| Employees | 29 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed SRPT by 106.8 percentage points over the past year.
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
PVLA vs SRPT FAQ
Which is bigger, Palvella Therapeutics or Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.92B compared with $1.89B for Palvella Therapeutics (PVLA).
Which stock has performed better over the past year, PVLA or SRPT?
PVLA returned +84.66% over the past 12 months, compared with -22.11% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Palvella Therapeutics and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.